Advanced prostate cancer experimental radioactive treatment-clinical trial decision making: Patient experiences

Document Type

Journal Article

Publication Title

BMJ Supportive & Palliative Care

Publisher

BMJ Publishing Group

School

Exercise Medicine Research Institute

RAS ID

38774

Comments

Viljoen, B., Hofman, M. S., Chambers, S. K., Dunn, J., Dhillon, H., Davis, I. D., & Ralph, N. (2021). Advanced prostate cancer experimental radioactive treatment—clinical trial decision making: Patient experiences. BMJ Supportive & Palliative Care. Advance online publication. https://doi.org/10.1136/bmjspcare-2021-002994

Abstract

Objectives: Nested qualitative studies within clinical trials provide the opportunity to better understand participant experiences of participation and identify areas where improved support is required. The purpose of this qualitative study is to describe the lived experiences of men with advanced prostate cancer participating in the TheraP trial; a randomised trial of 177Lu-PSMA-617 compared with cabazitaxel chemotherapy. Methods: Fifteen men with advanced prostate cancer were recruited from the TheraP clinical trial and interviewed at three time points during the trial. Interviews were inductively analysed using thematic analysis. This research paper reports the results from the baseline interview at commencement of the trial, focusing specifically on participants' enrolment experiences. Results: Four themes were identified representing the lived experiences of men with advanced prostate cancer deciding to participate in the TheraP trial: (1) hoping to survive; (2) needing to feel informed; (3) choosing to participate and (4) being randomised. The process of deciding to enrol in a clinical trial is filled with indecision, emotional difficulties and focused on a desire to live. Conclusions: For men with advanced prostate cancer, the experience of deciding to enrol in a clinical trial is principally driven by a desire to survive but interlinked with the need to make an informed decision as participants in this study expressed a preference for allocation to the experimental arm. Men seeking to enrol in clinical trials of new prostate cancer treatments would benefit from improved informational and decision support. Trial registration number: NCT03392428, ANZUP1603.

DOI

10.1136/bmjspcare-2021-002994

Access Rights

subscription content

Share

 
COinS